Milgrom J, Holt C J, Bleker L S, Holt C, Ross J, Ericksen J, Glover V, O'Donnell K J, de Rooij S R, Gemmill A W
1Parent-Infant Research Institute,Heidelberg West,Victoria,Australia.
3Department of Clinical Epidemiology,Biostatistics and Bioinformatics,Amsterdam UMC, location AMC,Amsterdam,The Netherlands.
J Dev Orig Health Dis. 2019 Apr;10(2):221-231. doi: 10.1017/S2040174418000739. Epub 2018 Oct 10.
Effective treatment of maternal antenatal depression may ameliorate adverse neurodevelopmental outcomes in offspring. We performed two follow-up rounds of children at age 2 and age 5 whose mothers had received either specialized cognitive-behavioural therapy or routine care for depression while pregnant. Of the original cohort of 54 women, renewed consent was given by 28 women for 2-year follow-up and by 24 women for 5-year follow-up. Child assessments at the 2-year follow-up included the Parenting Stress Index (PSI), Bayley Scales of Infant Development (BSID-III) and the Child Behaviour Checklist (CBCL). The 5-year follow-up included the Wechsler Preschool and Primary Scales of Intelligence (WPPSI-III) and again the CBCL. Treatment during pregnancy showed significant benefits for children's development at age 2, but not at age 5. At 2 years, intervention effects were found with lower scores on the PSI Total score, Parent Domain and Child domain (d=1.44, 1.47, 0.96 respectively). A non-significant trend favoured the intervention group on most subscales of the CBCL and the BSID-III (most notably motor development: d =0.52). In contrast, at 5-year follow-up, no intervention effects were found. Also, irrespective of treatment allocation, higher depression or anxiety during pregnancy was associated with higher CBCL and lower WPPSI-III scores at 5 years. This is one of the first controlled studies to evaluate the long-term effect of antenatal depression treatment on infant neurodevelopmental outcomes, showing some benefit. Nevertheless, caution should be taken interpreting the results because of a small sample size, and larger studies are warranted.
有效治疗孕产妇产前抑郁症可能会改善后代不良的神经发育结局。我们对母亲在孕期接受过专门认知行为疗法或常规抑郁症护理的儿童进行了两轮随访,分别在他们2岁和5岁时进行。在最初的54名女性队列中,28名女性重新同意进行2年随访,24名女性重新同意进行5年随访。2年随访时对儿童的评估包括育儿压力指数(PSI)、贝利婴幼儿发育量表(BSID-III)和儿童行为量表(CBCL)。5年随访包括韦氏学前和小学智力量表(WPPSI-III)以及再次使用CBCL。孕期治疗对2岁儿童的发育显示出显著益处,但对5岁儿童则没有。在2岁时,干预组在PSI总分、父母领域和儿童领域得分较低,发现了干预效果(分别为d=1.44、1.47、0.96)。在CBCL和BSID-III的大多数子量表上,干预组有不显著的趋势占优(最明显的是运动发育:d =0.52)。相比之下,在5年随访时,未发现干预效果。此外,无论治疗分配如何,孕期较高的抑郁或焦虑与5岁时较高的CBCL得分和较低的WPPSI-III得分相关。这是首批评估产前抑郁症治疗对婴儿神经发育结局长期影响的对照研究之一,显示出了一些益处。然而,由于样本量小,在解释结果时应谨慎,需要开展更大规模的研究。